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Abstract 
We present an unusual case of metastatic
prostate adenocarcinoma that manifested with
multiple exophytic intravesical masses, mim-
icking  a  multifocal  primary  bladder  tumor.
Biopsy  with  immunohistochemical  analysis
confirmed  metastatic  prostate  adenocarcino-
ma. The patient was treated palliatively with
external beam radiotherapy to prevent possible
symptoms from local tumor progression. This
case  illustrates  that  when  a  patient  with
known prostate cancer presents with multifo-
cal bladder tumors, the possibility of metastat-
ic prostate cancer should be considered.
Case Report
In March 2003, a 60 year-old man was found
to  have  a  firm  prostate  on  routine  physical
exam. Workup revealed adenocarcinoma of the
prostate,  clinical  stage  T2b  N1  M0,  Gleason
score 4+3, and a pretreatment serum prostate
specific antigen (PSA) level of 106.4 ng/mL. He
was  treated  with  androgen  ablation  therapy
(AAT) for 6 years until March 2009, at which
time he developed a sign of castration-resistant
disease  with  a  progressively  rising  PSA.
Technetium  99m  whole  body  bone  scan  and
computed tomography (CT) scan revealed no
evidence of metastatic disease. He enrolled in a
phase II randomized clinical trial evaluating an
allogeneic whole cell vaccination with or with-
out autologous myeloid dendritic cells. After 12
months of vaccine therapy, his PSA slowly rose
to 25.8 ng/mL and restaging studies were per-
formed. In March 2010, a non-contrast CT of
the  abdomen  and  pelvis  revealed  a  polypoid
mass  in  the  urinary  bladder.  A  bone  scan
revealed a new focus of increased radiotracer
uptake in the right posterior 9th rib, consistent
with bone metastasis. A CT urogram revealed
multiple nodular filling defects arising from the
left  posterior  bladder  wall  about  the
ureterovesicular junction, worrisome for multi-
focal  urothelial  carcinoma  (Figure  1).  The
prostate was normal in appearance and there
was no suggestion of contiguous involvement
between the prostate and the bladder masses.
There  was  no  evidence  of  hydronephrosis.
Serum creatinine was 1.0 mg/dL. The patient
denied hematuria or urinary obstructive symp-
toms. Cystoscopy revealed a normal prostatic
urethra and bladder neck. On the left bladder
wall and left trigone, there were 10-15 spherical
superficial masses measuring 1-3 cm in diam-
eter (Figure 2). Biopsy of one of the masses
revealed poorly differentiated prostatic adeno-
carcinoma (Gleason 5+5) (Figure 3). Immuno  -
histochemical stains of the tumor cells were
positive for PSA and prostatic acid phosphatase
(PAcP) and negative for keratin 903.
The  patient  was  referred  to  the  radiation
oncology department for consideration of pal-
liative radiotherapy to the prostate and urinary
bladder masses. Clinical exam of the prostate
revealed  a  diffusely  firm  and  nodular  gland
with extension of induration to the left semi-
nal  vesicle,  consistent  with  known  locally
advanced  prostate  adenocarcinoma.  At  the
time he was asymptomatic from these lesions;
however, there was concern that progressive
tumor  growth  would  lead  to  local  symptoms
including hematuria, urinary obstruction, irri-
table  voiding  symptoms,  and/or  ureteral
obstruction.  He  was  treated  palliatively  with
external  beam  radiotherapy  with  a  total
planned dose of 50 Gy in 20 fractions delivered
to the entire bladder and prostate. To reduce
potential radiation toxicity, the treatment was
delivered in a planned split course schedule of
25 Gy in 10 fractions, followed by a three-week
break, and then another 25 Gy in 10 fractions.
The patient tolerated the treatment well with
only  mild  increased  urinary  frequency  and
diarrhea, which resolved after the completion
of  radiotherapy.  Following  the  completion  of
radiotherapy, the patient was initiated on sys-
temic chemotherapy with docetaxel for castra-
tion recurrent prostate cancer.
Discussion
The most common tumor occurring in the
urinary bladder is a primary urothelial carcino-
ma.
1 Secondary tumors of the urinary bladder
are rare, accounting for 2-13% of all urinary
bladder  tumors.
1,2 Secondary  tumors  can
involve the bladder through direct extension,
as in the case of colon/rectum, prostate, and
cervix  primaries,  or  through  hematogenous
spread from distant organs.
2 The tissue of ori-
gin  can  usually  be  elucidated  by  means  of
immunohistochemical  staining  characteris-
tics.  Positive  immunostaining  for  PSA  and
PAcP is characteristic of prostate adenocarci-
noma and can be used to distinguish from pri-
mary adenocarcinoma of the urinary bladder or
secondary  involvement  from  colorectal  or
endometrial adenocarcinoma.
2
In the era of PSA testing, urinary bladder
involvement  by  prostate  cancer  is  relatively
uncommon.
3 Most  cases  of  bladder  involve-
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Figure 1. Axial computed tomography uro-
gram showed multiple nodular and spheri-
cal filling defects of the urinary bladder.[Rare Tumors 2010; 2:e65] [page 187]
ment  represent  direct  tumor  extension  of
uncontrolled  local  disease  in  either  locally
advanced  prostate  cancer  at  presentation  or
recurrent  local  disease  after  the  failure  of
definitive therapy. Bates et al. reported a clini-
copathologic series of 282 patients with sec-
ondary urinary bladder tumors. Of this cohort,
54 cases were due to prostate adenocarcino-
ma.
2 A majority of these 54 cases had a solitary
mass  in  the  bladder  neck  or  trigone,  which
likely  represents  direct  tumor  extension  of
uncontrolled  local  disease  into  the  bladder,
based on the location and unifocality of the
lesion. Only one patient had multifocal bladder
involvement that could indicate a hematoge-
nous  spread.  In  an  autopsy  study  of  1367
patients  with  metastatic  adenocarcinoma  of
the prostate, urinary bladder involvement was
noted  in  39%  of  patients.
4 Others  described
case reports of isolated tumor recurrence of
prostate adenocarcinoma in the urinary blad-
der several years after radical prostatectomy,
which  likely  typifies  a  local  recurrence  of
prostate  cancer  in  the  region  of  the  vesi-
courethral anastamosis.
5-7
Multifocal involvement of the urinary blad-
der by prostate adenocarcinoma, as seen in our
case, is very rare, and presents a diagnostic
challenge.  It  can  represent  a  hematogenous
spread, direct local extension, or a combina-
tion of both. Recently, Camilot et al. described
two  patients  with  prostate  adenocarcinoma
presenting  with  dysuria  who  were  found  to
have multiple polypoid lesions in the urinary
bladder.
8 The suspected clinical diagnosis was
a  primary  urinary  bladder  cancer,  although
biopsy  revealed  mixed  polypoid  and  diffuse
linitis plastica-like infiltration of the bladder
wall. As illustrated in this report as well as our
case, when a patient presents with multifocal
urinary  bladder  tumors,  the  diagnosis  most
often considered is multifocal primary urothe-
lial carcinoma, even in the setting of known
prostate  adenocarcinoma.  Invariably,  a  cys-
toscopy  with  biopsy  and  immunostaining  is
required to establish a correct diagnosis of pro-
static  adenocarcinoma.  Systematic  biopsy  of
the bladder neck may be of use in distinguish-
ing contiguous spread from the prostate versus
hematogenous spread.
In the previously described cases and ours,
multifocal urinary bladder involvement by pro-
static adenocarcinoma occurred late in the dis-
ease  course,  thus  any  potential  treatments
would  be  considered  palliative  in  nature.
8,9
While  previously  reported  patients  had  pre-
sented with urinary symptoms, our patient was
asymptomatic with the urinary bladder lesions
found  incidentally  on  restaging  CT  of  the
abdomen  and  pelvis.
8 We  elected  to  deliver
radiotherapy to the prostate and urinary blad-
der to prevent the development of symptoms
from local progression, although the decision
to  treat  this  asymptomatic  patient  could  be
considered  controversial.
9 The  radiotherapy
was delivered in a split course in order to min-
imize radiation toxicity. Similar hypofraction-
ated  palliative  radiotherapy  regimens  have
been successfully used for symptomatic locally
advanced prostate adenocarcinoma or urothe-
lial carcinoma with minimal acute toxicity.
10,11
In retrospect, this patient may have benefitted
from  definitive  therapy  using  a  combined
treatment of radiotherapy plus AAT at initial
diagnosis. Recently, phase III randomized tri-
als have demonstrated improved locoregional
control and overall survival with combined AAT
and radiotherapy compared to AAT alone for
patients with newly diagnosed locally advanced
adenocarcinoma of the prostate.
12,13
In  summary,  our  case  represents  a  rare
instance of multifocal involvement of the uri-
nary  bladder  by  prostate  adenocarcinoma,
mimicking a multifocal primary bladder tumor.
Case Report
Figure 2. Cystoscopic exam revealed mul-
tiple  exophytic  masses  arising  from  the
urinary bladder lumen.
Figure 3. The urinary bladder biopsy showed a poorly differentiated adenocarcinoma
characterized by tumor cells showing large pleomorphic nuclei with prominent nucleoli
(image A and B).  Immunohistochemical stains were performed and the tumor cells were
positive for prostate specific antigen (PSA; image C) and prostatic acid phosphatase
(PAcP; image D), supporting a diagnosis of metastatic prostate cancer.[page 188] [Rare Tumors 2010; 2:e65]
This illustrates that when a patient with late-
stage prostate cancer presents with multifocal
bladder  tumors,  the  possibility  of  metastatic
prostate cancer should be considered. A biopsy
with immunohistochemical analysis is neces-
sary to make the correct diagnosis.
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